Insights & news

"National Healthcare Insurance Systems Are Allowed To Reimburse Off-Label Use of Medicine" Says ECJ

  • 22/11/2018
  • Articles

The Court of Justice of the European Union (“ECJ”) held this morning that under EU law national healthcare insurance systems are allowed to reimburse a medicine for a use not covered by that product’s marketing authorisation (see attached – Case C-29/17, Novartis and others v. Agenzia Italiana del Farmaco and others, judgment of 21 November 2018). The ECJ’s judgment came at the request of the Italian Council of State which had been asked to handle litigation between Novartis and various Italian health authorities over the reimbursement of Avastin for off-label use in the management of the eye-condition wet age-related macular degeneration (“AMD”). Avastin functions in that case as a replacement for Roche’s significantly more expensive Lucentis. For its part, Avastin has a marketing authorisation for a range of unrelated oncology indications.
As is the case in a number of other Member States, Italian law provides for a mechanism that allows for the reimbursement of a non-authorised indication for financial reasons, even if there is an alternative authorised therapy on the market. In its challenge of the reimbursement of the off-label use of Avastin, Novartis relied in part on EU medicines law. Today’s ruling of the ECJ dooms that effort.
The ECJ’s verdict would seem to be predicated on the fundamental principle that the “organisation and management of health services and the allocation of resources assigned to them are the responsibility of the Member States” (Novartis, §49). The ECJ added that Member States thus have the power to regulate the consumption of medicines in order to “promote the financial stability of their healthcare insurance schemes” (Id., §48).
On that basis, the ECJ maintained that Italy was in its right to reimburse the off-label use of Avastin despite the availability of more expensive alternatives. The ECJ went on to state that, in the process, Italy duly observed the EU medicine rules. For example, the ECJ found that the repackaging of Avastin to accommodate the use not contemplated by its marketing authorisation does not require a new authorisation because that process (i) does not modify the medicine; (ii) is prescribed by a physician (who under most national laws bears the ultimate responsibility for off-label prescriptions); and (ii) is undertaken by pharmacies authorised to have that product administered in hospitals.
Similarly, the ECJ considered that the pharmacovigilance system provided for by EU law also applies to off-label use.
The ECJ thus sided with its Advocate General who, at the end of July 2018, had already reached a similar conclusion (see, VBB Life Sciences Newsflash of 30 August 2018).     


Key contacts

Related practice areas

Related insights

Sign up for updates
    • 03/12/2018
    • Articles

    Five Further Member State Inspectorates Recognised under EU - US Mutual Recognition System for Medicines

    The Agreement on Mutual Recognition between the European Union and the United States of America continues its roll-out in the realm of pharmaceutical inspections. On two separate occasions in November 2018, the US Food and Drug Administration (“FDA”) added 5 new EU Member States to its list of countries which it considers to have capable inspectorates to carry out good manufacturing practice (“GMP”) inspections at a level equivalent to that observed in the US. These Member States are Belgium, Denmark, Estonia, Finland and Latvia. The updated list of in total 20 Member States whose inspection results the FDA considers can replace its own inspections can be found here: The EU and the US thus seem to be on track to have all EU Member States recognised as capable of carrying out pharmaceutical inspections by 15 July 2019. For its part, the FDA had already been earmarked as a capable inspectorate on 1 November 2017.

    Read more
    • 30/11/2018
    • Articles

    OECD - Pharmaceutical Innovation and Access to Medicines

    The Organisation for Economic Cooperation and Development (“OECD”) has just published a study on Pharmaceutical Innovation and Access to Medicines (the “Study” - available here: Pharmaceutical Innovation and Access to Medicines). The Study forms a response to a request by 35 member countries to prepare a report detailing the challenges for governments in ensuring that their populations have access to novel medicines at a reasonable cost while at the same time maintaining the pharmaceutical sector’s capacity for innovation.

    Read more
    • 16/11/2018
    • Articles

    Novelties regarding Clinical Trials - Law of 30 October 2018 containing Miscellaneous Provisions regarding Health

    The Belgian Official Journal publishes today a Law of 30 October 2018 containing miscellaneous provisions regarding health. The attached case note sheds light on new rules governing clinical trials.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *